Comparison of the Mean Duration of 3rd Stage of Labour Between Intraumbilical and Intravenous Oxytocin

NCT07053930 | Completed

• 1 other identifier: DRANAMJAVED
• Study Type: interventional
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

There is always a debate for choosing the best method for management of the third stage of labour (TSL) in the general practice for reducing the duration of TSL. Although intravenous oxytocin is more extensively used in general practice for managing TSL than intraumbilical, it still needs to be properly investigated among local populations and in local settings.

Conditions

Labor

Outcome Measures

Primary Outcomes (1)

• Duration of the third stage labour

  The duration of the third stage labour was measured from the completed delivery of the newborn until the completed delivery of the placenta.

  30 minutes

Study Arms (2)

Intraumbilical oxytocin group

EXPERIMENTAL

Patients were given 10 U of intraumbilical oxytocin, diluted in 10 mL of normal saline.

Drug: Intraumbilical oxytocin

Intravenous oxytocin group

EXPERIMENTAL

Patients received 20 U of intravenous oxytocin diluted in 500 mL of normal saline.

Drug: Intravenous oxytocin

Interventions

Intraumbilical oxytocin DRUG

Patients were given 10 U of intraumbilical oxytocin, diluted in 10 mL of normal saline.

Intraumbilical oxytocin group

Intravenous oxytocin DRUG

Patients received 20 U of intravenous oxytocin diluted in 500 mL of normal saline.

Intravenous oxytocin group

Eligibility Criteria

• Age: 18 Years - 40 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Females aged 18-40 years
• With spontaneous vaginal delivery
• Singleton pregnancy
• Gestational age \>37 weeks
• Parity l-5
• Any gravidity

You may not qualify if:

• Females with intrauterine fetal death
• Malpresentation
• Multiple pregnancy
• Polyhydramnios
• Premature rupture of membranes
• Medical disorders and hypertensive disorders of pregnancy

Sponsors & Collaborators

• RESnTEC, Institute of Research: lead

Study Sites (1)

Sadiq Abbasi Hospital

Bahawalpur, Punjab Province, 63100, Pakistan

Location

Study Officials

• Anam Javed

  Sadiq Abbasi Hospital, Bahawalpur, Pakistan

  PRINCIPAL INVESTIGATOR

• Komal Iqbal

  Sadiq Abbasi Hospital, Bahawalpur, Pakistan

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 27, 2025
• First Posted: July 8, 2025
• Study Start: October 1, 2024
• Primary Completion: March 31, 2025
• Study Completion: March 31, 2025
• Last Updated: July 8, 2025

Record last verified: 2025-06

Data Sharing

• IPD Sharing: Will not share

Locations

PA (1)